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Abstract
In this work, we describe the ‘green’ synthesis of novel 6-(adamantan-1-yl)-2-substituted-
imidazo[2,1-b][1,3,4]thiadiazoles (AITs) by ring formation reactions using 1-(adamantan-1-
yl)-2-bromoethanone and 5-alkyl/aryl-2-amino1,3,4-thiadiazoles on a nano material base in
ionic liquid media. Given the established activity of imidazothiadiazoles againstM. tubercu-
losis, we next examined the anti-TB activity of AITs against the H37Rv strain using Alamar
blue assay. Among the tested compounds 6-(adamantan-1-yl)-2-(4-methoxyphenyl)imi-
dazo[2,1-b][1,3,4]thiadiazole (3f) showed potent inhibitory activity towardsM. tuberculosis
with an MIC value of 8.5 μM. The inhibitory effect of this molecule againstM. tuberculosis
was comparable to the standard drugs such as Pyrazinamide, Streptomycin, and Ciproflox-
acin drugs. Mechanistically, an in silico analysis predicted sterol 14α-demethylase (CYP51)
as the likely target and experimental activity of 3f in this system corroborated the in silico tar-
get prediction. In summary, we herein report the synthesis and biological evaluation of
novel AITs againstM. tuberculosis that likely target CYP51 to induce their antimycobacter-
ial activity.
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Introduction
Tuberculosis (TB) is one of the leading contagious and airborne disease caused byMycobacte-
rium tuberculosis [1, 2] and according to 2013 report of World Health Organization, TB stands
second in terms of global mortality from a single infectious agent with 1.5 million death in
2013 worldwide. The conventional TB treatment comprises a cocktail of first-line drugs,
namely isoniazid, pyrazinamide, ethambutol and rifampicin which are associated with lowered
efficacy due to resistance development and severe adverse effects [3, 4]. The subsequent use of
second-line drugs were also reported to suffer from similar problems [5–7]. Gradual increase
of multidrug and extensively drug resistant (XDR-TB) mycobacterial strains demands the need
of new therapeutic agents which can effectively target TB. The presence of lipid-rich cell surface
on mycobacterium provides an effective therapeutic target to design anti-TB agents [8].
Researchers have rightly called adamantanyl ring as ‘lipophilic bullet’ which effectively targets
mycobacterium. Evidently, hybrid obtained from the coupling of adamantylacetamide ring
with 1,2,3-triazoles resulted in development of potent inhibitors againstM. tuberculosis [2].
Adamantyl urea derivatives were reported to induce antimycobacterial action againstM. tuber-
culosis [9]. SQ109, an adamantane based small molecule which is in phase-II clinical trials for
the treatment of pulmonary TB [10–12]. On the other hand, Delamanid, an imidazo-oxazole
based anti-tuberculosis drug was approved for the treatment of multidrug-resistant tuberculo-
sis [13]. Thiadiazoles and imidazothiadiazoles were reported to have antitubercular activity
againstM. tuberculosisH37Rv strains [14–16]. Based on these reports, we attempted to tether
the imidazo-thiadiazole nuclei to adamantyl ring in order to enhance the bioactivity profile of
the newer drug-seeds. We previously developed several heterocycle based small molecules and
explored the various pharmacological properties [17–25]. In the present report, we synthesized
a series of novel adamantanyl-tethered imidazo-thiadiazoles for the first-time and evaluated
for their inhibitory activity towardsM. tuberculosis, and a subsequent mode-of-action analysis
identified that they likely achieve this activity by targeting sterol 14α-demethylase (CYP51) (S1
Data).
Results and Discussion
Chemistry
The reaction between 1-(adamantan-1-yl)-2-bromoethanone and 5-substitued-2-amino-
1,3,4-thiadiazoles yielded 6-(adamantan-1-yl)-2-substituted-imidazo[2,1-b][1,3,4]thiadiazoles
(‘AITs’) with varying yields under different base and solvent conditions (Fig 1A, Scheme 1).
Use of solvents such as ethanol, 1-butanol, N,N-dimethyl formamide resulted in poor yields. In
order to overcome yield limitation, we next used various ionic liquids (ILs) in combination
with a nano-catalyst, nano-MgO (Table 1) [26, 27]. ILs are molten salts, which can dramatically
accelerate the rate of reactions, and have often been found to be a suitable substitute for low-
boiling organic solvents in terms of toxicity, volatility and flammability [28]. In addition, ILs
have more favorable ‘green’ properties, since they are reusable. In the current work, replace-
ment of organic solvents with ILs significantly improved yields of the product to greater than
90%. In particular, [BMIM]+[BF4]
- and [BMPy]+[PF6]
- were found to be the better ILs and we
have chosen [BMIM]+[BF4]
- for the preparation of compounds due to its solubility in water.
Additionally, this method was found to be green protocol for the preparation of alkyl or aryl
substitution on thiadiazole ring (Table 2). All the isolated products of the reaction were fully
characterized by 1H NMR, LC-MS and elemental analysis. Finally, we prepared the single crys-
tal of one of the AITs, namely 3b, via slow evaporation technique. The single crystal X-ray dif-
fraction studies of 3b confirmed formation of the title compounds (Fig 1B).
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Anti-TB activity of novel AITs
The in vitro Alamar Blue assay was employed to determine the Anti-TB activity of AITs against
theM. tuberculosis H37Rv strain as described earlier [29]. Various concentrations of AITs were
added to the culture ofM. tuberculosis and minimum inhibitory concentrations (MIC) of AITs
were measured and the results are tabulated in Table 2. Most AITs showed inhibitory activity
towards theM. tuberculosisH37Rv strain, suggesting that AITs possess significant anti-TB
activity. Notably, Compound 3a, 3f, and 3i dispalyed relatively low MIC values of 10.5, 8.5 and
12.5 μM respectively when compared to the other structurally related compounds. Compounds
with electron-donating phenyl, 4-methoxy phenyl, and methyl substituents attached to the imi-
dazo-thiadiazole scaffold were favorable for activity againstM. tuberculosis.
In silicomolecular interactions of AITs towards sterol 14α-demethylase
As sterol 14α-demethylase (CYP51) is known to process a variety of sterols and as a drug target
inM. tubercolosis [30, 31], we attempted to rationalize the anti-TB activity of the AITs synthe-
sized in this work on a structural basis. Therefore, we docked all AITs to the X-ray structure of
M. tubercolosis CYP51 in complex with a small molecule inhibitor (PDB: 2CIB) [32] using MOE
default settings (Fig 2A) [33] and visualized predicted protein-ligand interactions with Pymol
[34]. It was found that the imidazo-thiadiazole scaffold of 3f likely interacts with the heme co-fac-
tor of CYP51 (see Fig 2B). Furthermore, the hydrophobic moieties are positioned in similar posi-
tions to the ring centers found in the co-crystallized ligand. Based on this analysis, CYP51
appeared to be a plausible target for AITs on a structure-based level. Further, in order to analyze
the similarities in binding mode between AITs, we superposed the ligand in the co-crystal used
for docking with compound 3a using MOE's flexible alignment module and default settings [33].
We found an almost perfect shape overlap of the lowest energy conformations of AITs with all
hydrophobic centers coinciding with the co-cyrstallized ligand (see Fig 2C). Therefore, the AITs
Fig 1. A) Schematic representation of the preparation of AITs. B) ORTEP diagram of 3b. The compound crystallizes in a triclinic system under the space
group P-1, and the benzyl imidazothiadiazole moiety adopts a chair conformation with the benzyl imidazothiadiazole moiety and the phenyl ring being
bridged by the carbon atom (C6) with a dihedral angle of 69.73 degrees.
doi:10.1371/journal.pone.0139798.g001
Table 1. Cyclocondensation of 5-Phenyl-2-amino-1,3,4-thiadiazole (2) with 1-Adamantyl bromomethylketone (1) under various reaction conditions
to form title compounds. It can be seen that using nano-MgO as a base and employing ionic liquids instead of traditional organic solvents considerably
increase yields above 90%.
Entry Reaction conditions Reaction time (h) Yield (%)
1 Ethanola / Na2CO3 36 37
2 1-Butanolb / MgO 42 38
3 N,N-DMFc /Et3N 30 30
4 1-Butyl-3-methyl imidazolium tetraﬂuoroborated/ Na2CO3 25 68
5 1-Butyl-4-methyl pyridinium hexaﬂuorophosphated/ K2CO3 24 55
6 1-Butyl-3-methyl imidazolium tetraﬂuoroborated/ Et3N 24 58
7 1-Butyl-4-methyl pyridinium hexaﬂuorophosphated/ MgO 14 64
8 1-Butyl-3-methyl imidazolium tetraﬂuoroborated/ MgO 11 71
9 1-Butyl-3-methyl imidazolium tetraﬂuoroborated/Nano MgO 3 93
10 1-Butyl-4-methyl pyridinium hexaﬂuorophosphated/ Nano MgO 3 95
aReaction temperature = 80°C
bReaction temperature = 95°C
cReaction temperature = 120°C
dReaction temperature = 60°C.
doi:10.1371/journal.pone.0139798.t001
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presented in this work could be considered a continuation of the 1,3,4-thiadizole series presented
earlier by Oruc et al. [16] including an isosteric replacement of the core ring fragment.
In vitro anti-microbial activity of AITs against fungal strains that express
14α-demethylase (CYP51)
Our in vitro and in silico studies revealed that AITs showed good anti-TB activity at the low
micro molar concentrations, and by plausibly targeting sterol 14α-demethylase (CYP51). In order
to find further experimental support for the mode-of-action analysis of the AITs presented here,
the CM237 and akuB strains of A. fumigatus that express CYP51 were selected for the next step.
We further investigated the effect of AITs at various concentrations against both the fungal strains
by broth microdilution method as reported previously [35]. MICs were determined visually in
duplicate and recorded after 48 h. Results are summarized in Table 3. Interestingly, the most
active compounds againstM. tuberculosis, namely 3a, 3f, and 3i also exhibited significant inhibi-
tory effect against the tested A. fumigates strains. These results lend further support–though not
definite proof to their plausible mode-of-action by targeting sterol 14α-demethylase (CYP51).
Materials and Methods
All solvents used were of analytical grade and reagents used were purchased from Sigma-
Aldrich chemicals. All IR spectra were obtained in a KBr disc on a Shimadzu FT-IR 157 Spec-
trometer. 1H and 13C NMR spectra were recorded on a Bruker WH-200 (400 MHz) in CDCl3
Table 2. Cyclocondensation of 5-alkyl/aryl-2-amino-1,3,4-thiadiazole (1a-j) with 1-adamantyl bromomethylketone to form (3a-j).
Entry R Product (3a-j) Reaction time
(h)
Yield
(%)
Melting point
(°C)
Alamar Blue
Activity (μM)
3a C6H5 6-(adamantan-1-yl)-2-phenylimidazo[2,1-b][1,3,4]
thiadiazole
3 83 142 10.5
3b CH2C6H5 6-(adamantan-1-yl)-2-benzylimidazo[2,1-b][1,3,4]
thiadiazole
2 79 112 30.7
3c 4-NO2- C6H4 6-(adamantan-1-yl)-2-(4-nitrophenyl)imidazo[2,1-b]
[1,3,4]thiadiazole
3 79 163 28.7
3d 4-OCH3-
C6H4CH2
6-(adamantan-1-yl)-2-(4-methoxybenzyl)imidazo
[2,1-b][1,3,4]thiadiazole
2 86 126 32.7
3e C4H3O 6-(adamantan-1-yl)-2-(furan-2-yl)imidazo[2,1-b]
[1,3,4]thiadiazole
2 77 131 38.2
3f 4-OCH3-C6H4 6-(adamantan-1-yl)-2-(4-methoxyphenyl)imidazo
[2,1-b][1,3,4]thiadiazole
2 84 157 8.5
3g 4-Br-C6H4 6-(adamantan-1-yl)-2-(4-bromophenyl)imidazo
[2,1-b][1,3,4]thiadiazole
3 81 161 20.0
3h C6H11 6-(adamantan-1-yl)-2-cyclohexylimidazo[2,1-b]
[1,3,4]thiadiazole
2 74 198 36.5
3i CF3 6-(adamantan-1-yl)-2-(triﬂuoromethyl)imidazo
[2,1-b][1,3,4]thiadiazole
2 63 >300 12.0
3j CH3 6-(adamantan-1-yl)-2-methylimidazo[2,1-b][1,3,4]
thiadiazole
2 67 203 22.7
Pyrazinamide 12.5
Streptomycin 5.3
Ciproﬂoxacin 4.5
Equimolar mixture of 1a-j, and 2 was dissolved in 2 ml of [BMIM]+[BF4]
- and the reaction was carried out in the presence of 0.1 equivalent of Nano MgO at
60 0C.
doi:10.1371/journal.pone.0139798.t002
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or DMSO-d6 as solvent, using tetramethylsilane (TMS) as an internal standard and chemical
shifts are expressed as ppm. Mass spectra were determined on a Shimanzu LC-MS. The ele-
mental analyses were carried out using an Elemental Vario Cube CHNS rapid Analyzer. The
progress of the reaction was monitored by TLC pre-coated silica gel G plates.
Typical procedure for the synthesis of AITs
Amixture of 5-alkyl/aryl-2-amino1,3,4-thiadiazole (0.01 mol), 1-adamantyl bromomethylke-
tone (0.01 mol) and nano magnesium oxide (0.001 mol) in 2 ml of 1-Butyl-3-methylimidazo-
lium tetrafluoroborate [BMIM]+[BF4]
- was stirred at 60°C for the appropriate time (Table 2).
After completion of the reaction, as determined by TLC, the reaction mixture was cooled down
and then quenched into ice water. The product was extracted from the water layer by 3×5 mL
diethyl ether, dried with magnesium sulfate, filtered, and concentrated in vacuo. The crude
product was purified by chromatography employing a column of 30 mm diameter using 60–
120 silica gel and hexane/ethyl acetate (80:20) as mobile phase. All new compounds exhibited
spectral properties consistent with the assigned structures (S2 Data).
6-(Adamantan-1-yl)-2-phenylimidazo[2,1-b][1,3,4]thiadiazole (3a): 1H NMR (400 MHz,
CDCl3) δ: 8.0 (s, 1H), 7.8 (m, 2H), 7.6 (m, 2H), 7.4 (m, 1H), 2.1 (m, 6H), 1.9 (m, 3H), 1.7
(m,6H); 13C NMR (CDCl3): 175.73, 134.92, 133.26, 132.17,129.39, 128.09, 127.56, 123.43,
45.59, 42.75, 38.19, 28.48; LCMS (MM:ES+APCI) 336.3 (M+H)+; Anal.Calcd for C20H21N3S: C
71.61; H 6.31; N 12.53. Found: C, 71.43; H, 6.47; N, 12.66.
6-(Adamantan-1-yl)-2-benzylimidazo[2,1-b][1,3,4]thiadiazole (3b): 1H NMR (400 MHz,
CDCl3) δ: 8.0 (s, 1H), 7.4 (m, 2H), 7.3 (m, 3H), 4.4 (s, 2H), 1.7–2.2 (m,15H);
13C NMR
(CDCl3); 161.09, 135.82, 134.73, 129.04, 128.23, 125.56, 123.65, 45.56, 42.78, 38.65, 38.32,
28.66; LCMS (MM:ES+APCI) 350.3(M+H)+; Anal. Calcd for C21H23N3: C, 72.17; H, 6.63; N,
12.02. Found: C, 71.98; H, 6.78; N 12.24.
6-(Adamantan-1-yl)-2-(4-nitrophenyl)imidazo[2,1-b][1,3,4]thiadiazole (3c): 1H NMR
(400 MHz, CDCl3) δ: 8.1 (d, 2H), 8.0 (s, 1H), 7.9 (d, 2H), 2.1(m,6H),1.9(m, 3H), 1.7(m,6H);
13C NMR (CDCl3); 175.64, 148.97, 139.92, 135.33, 134.83, 128.65, 123.34, 121.78, 45.56, 42.78,
38.12, 28.55; LCMS (MM:ES+APCI) 381.2 (M+H)+; Anal. Calcd for C20H20N4O2S: C, 63.14;
H, 5.30; N, 14.73. Found: C, 63.18; H, 5.88; N, 13.89.
6-(Adamantan-1-yl)-2-(4-methoxybenzyl)imidazo[2,1-b][1,3,4]thiadiazole (3d): 1H
NMR (400 MHz, CDCl3) δ: 8.0 (s, 1H), 7.9 (d, 2H), 7.6 (d, 2H), 4.3 (s, 3H), 4.0 (s, 2H), 2.1 (m,
6H),1.9(m, 3H), 1.7(m, 6H); 13C NMR (CDCl3); 161.06, 159.43, 135.92, 134.83, 130.33, 128.23,
123.45, 114.45, 55.89, 45.56, 42.78, 38.22, 28.51; LCMS (MM:ES+APCI) 380.2 (M+H)+; Anal.
Calcd for C22H25N3OS: C, 69.62; H, 6.64; N, 11.07. Found: C, 69.48; H, 7.03; N, 11.86.
6-(Adamantan-1-yl)-2-(furan-2-yl)imidazo[2,1-b][1,3,4]thiadiazole (3e): 1H NMR
(400 MHz, CDCl3) δ: 8.1 (d, 1H), 8.00 (s, 1H), 7.4 (d, 2H), 6.8 (t, 1H), 2.1 (m, 6H), 1.9 (m, 3H),
Fig 2. Computational bindingmode analysis of AITs andM. tubercolosis CYP51. A) X-ray structure of CYP51 (green cartoon representation with heme
cofactor as sticks with bound iron as brown sphere) in complex with a small molecule inhibitor (PDB: 2CIB). B) Similar interactions and an analogous three-
dimensional arrangement are shown for compound 3f of the AITs (cyan sticks). C) Overlay of the parent 1,3,4-thiadiazole of Oruc et al [Oruc04] with
compound 3a of the AITs. Positioning of ring centers, exit vectors, and overall shape are very similar, thereby plausibly explaining a similar bioactivity profile.
doi:10.1371/journal.pone.0139798.g002
Table 3. MIC values obtained from the lead AIT compounds against A. fumigates, which expresses CYP51. Given the activity of compounds in this
system this finding corroborates CYP51 as a plausible target of the AIT series.
Aspergillus fumigatus strain Compound 3a MIC (μg/ml) Compound 3f MIC (μg/ml) Compound 3i MIC (μg/ml)
WT 237 16 16 16
WT akuB 8 8 8
doi:10.1371/journal.pone.0139798.t003
Synthesis of CYP51 Targeting Anti-Tuberculosis Agent
PLOS ONE | DOI:10.1371/journal.pone.0139798 October 15, 2015 7 / 12
1.7 (m, 6H); 13C NMR (CDCl3); 146.29, 142.97, 135.92, 134.83, 123.65, 107.45, 105.66, 45.56,
42.78, 38.22, 28.51; LCMS (MM:ES+APCI) 326.3 (M+H)+; Anal. Calcd for C18H19N3OS: C,
66.43; H, 5.88; N, 12.91. Found: C, 65.83; H, 6.05; N, 13,44.
6-(Adamantan-1-yl)-2-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazole (3f): 1H
NMR (400 MHz, CDCl3) δ: 8.2 (d, J = 8.4 Hz, 1H), 8.00 (s, 1H), 7.8 (d, 2H), 4.4 (s, 3H), 2.1
(m,6H), 1.9–1.7(m,9H); 13C NMR (CDCl3); 175.11, 160.63, 135.99, 134.83, 128.79, 125.32,
123.65, 114.45, 55.79, 45.56, 42.78, 38.22, 28.51; LCMS (MM:ES+APCI) 366.6 (M+H)+; Anal.
Calcd for C21H23N3OS: C, 69.01; H, 6.34; N, 11.50. Found: C, 68.33; H, 5.89; N,11.10.
6-(Adamantan-1-yl)-2-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazole (3g): 1H NMR
(400 MHz, CDCl3) δ: 8.3 (d, 2H), 8.1 (d, 2H), 8.0 (s, 1H), 2.0 (m, 6H),1.8 (m, 3H), 1.6 (m, 6H);
13C NMR (CDCl3); 175.14, 135.92, 134.87, 132.36, 129.56, 123.65, 45.57, 42.78, 38.29, 28.55;
LCMS (MM:ES+APCI) 415.1 (M+H)+; Anal. Calcd for C20H20BrN3S: C, 57.97; H, 4.87; N,
10.14. Found: C, 57.01; H, 4,22; N, 9.56.
6-(Adamantan-1-yl)-2-cyclohexylimidazo[2,1-b][1,3,4]thiadiazole (3h): 1H NMR (400 MHz,
CDCl3) δ: 8.0 (s, 1H), 2.7 (m, 2H), 2.1–1.8 (m, 15H), 1.7 (m, 6H), 1.5–1.4 (m, 3H);
13C NMR
(CDCl3); 135.89, 134.88, 123.67, 45.61, 42.83, 38.29, 33.27, 28.58, 27.95, 25.46; LCMS (MM:ES+
APCI) 342.3 (M+H)+; Anal. Calcd for C20H27N3S: C, 70.34; H, 7.97; N, 12.30. Found: C, 70.87; H,
8.54; N, 11.67.
6-(Adamantan-1-yl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazole (3i): 1H NMR
(400 MHz, CDCl3) δ: 8.0 (s, 1H), 2.1 (m,6H),1.9 (m, 3H), 1.7 (m,6H);
13C NMR (CDCl3);
135.92, 134.88, 123.55, 45.54, 42.72, 38.21, 28.54, 17.34; LCMS (MM:ES+APCI) 328.4(M+H)+;
Anal. Calcd for C15H16F3N3S: C, 55.03; H, 4.93; N, 12.84. Found: C, 55.37; H, 4.44; N, 12.13.
6-(Adamantan-1-yl)-2-methylimidazo[2,1-b][1,3,4]thiadiazole (3j): 1H NMR (400 MHz,
CDCl3) δ: 8.0 (s, 1H), 2.8 (s, 3H), 2.1 (m,6H), 1.9 (m, 3H), 1.7 (m,6H);
13C NMR (CDCl3);
157.89, 135.92, 134.83, 123.65, 118.45, 45.56, 42.78, 38.22, 28.51; LCMS (MM:ES+APCI) 274.4
(M+H)+; Anal. Calcd for C18H14FNO: C, 65.90; H, 7.00; N, 15.37. Found: C, 66.09; H, 7.65; N,
15.89.
X-ray crystal structure determination of (3b)
A single crystal of compound 3b with dimensions of 0.30 × 0.25 × 0.20 mm was chosen for
X-ray diffraction studies. The data were collected on a Bruker SMART APEX II X-ray diffrac-
tometer with Cu Kα radiation. Raw data was processed and reduced by using APEX2 and
SAINT [36, 37]. The crystal structure was solved by direct methods using SHELXS-97 [38]. All
non-hydrogen atoms were revealed in the first Fourier map itself. Anisotropic refinement of
non-hydrogen atoms was started at this stage. Subsequent refinements were carried out with
anisotropic thermal parameters for non-hydrogen atoms and isotropic temperature factors
for the hydrogen atoms which were placed at chemically acceptable positions. Full-matrix
least squares refinement was carried out using SHELXL-97 [39] with a final residual value of
R1 = 0.079. The thermal ellipsoid plot [40] of the molecule at 50% probability is represented in
Fig 1B. The details of crystallographic information have been deposited at the CCDC with
number 1056579.
The crystal structure analysis showed that the compound 3b crystallizes in a triclinic system
under the space group P-1, with cell parameters a = 6.3060(5) Å, b = 10.4279(7) Å, c = 14.1099
(10) Å, α = 81.101(2)°, β = 79.845(2)°, γ = 82.918(2)° and Z = 2. The benzyl imidazothiadiazole
moiety adopts a chair conformation with puckering parameters Q = 0.622(4) Å and φ = 201(19)°
[31] and the maximum deviation found on the puckered atom at C14 is 0.255(3) Å. The benzyl
imidazothiadiazole moiety and the phenyl ring are bridged by the carbon atom (C6) with a dihe-
dral angle of 69.73(5)°. The structure does not contain any classical hydrogen bonds.
Synthesis of CYP51 Targeting Anti-Tuberculosis Agent
PLOS ONE | DOI:10.1371/journal.pone.0139798 October 15, 2015 8 / 12
Anti-tubercular activity assay
All the novel AITs were screened for anti-tubercular activity againstM. tuberculosisH37Rv
strain (ATCC 27294) using a microplate Alamar Blue assay (MABA) as described previously
[29, 31]. Briefly, 200 μl of sterile deionized water was added to all outer-perimeter wells of ster-
ile 96-well plates to minimize evaporation of the medium in the test wells during incubation.
The wells in rows B to G in columns 3 to 11 received 100 μl of Middlebrook 7H9 broth. 100 μl
of 2X drug solutions were added to the wells in rows B to G in columns 2. 100 μl was trans-
ferred from column 2 to column 3, and the contents of the wells were mixed well. Identical
serial 1:2 dilutions were continued through column 10, and 100 μl of excess medium was dis-
carded from the wells in column 10 in order to get the final concentration of 0.2 μg/ml. 100 μl
ofM. tuberculosis inoculum was added to the wells in rows B to G in columns 2 to 11 (yielding
a final volume of 200 μl per well). Thus, the wells in column 11 served as drug-free control. The
plate was sealed with parafilm and incubated at 37°C for 5 days. Thereafter, 50 μl of freshly pre-
pared 1:1 mixture of Alamar Blue reagent and 10% tween-80 was added to each well and incu-
bated for 24 h. Appearance of blue color was interpreted as no bacterial growth, and pink color
was used as indicator of bacterial growth. The inhibitory activity of AITs againstM. tuberculo-
sis was expressed as the minimum inhibitory concentration (MIC) in μM. MIC was defined as
lowest drug concentration which prevented the color change from blue to pink. Pyrazinamide,
streptomycin, and ciprofloxacin were used as a positive controls.
Molecular docking analysis
In silicomolecular docking was performed based on the X-ray structure ofM. tubercolosis
CYP51 in complex with a small molecule inhibitor (PDB: 2CIB) [32]. The ligand structures
were energy-minimized and protonated using the MOE platform [33]. The protein was pre-
pared for docking using protonate3D [41]. Afterwards, we docked all AITs to the X-ray struc-
ture of using MOE's default settings for flexible docking. This includes an initial placement
using Triangle Matcher, primary scoring via London dG and a forcefield refinement of 30
poses followed by a re-scoring step using GBVI/WSA dG. We visualized predicted protein-
ligand interactions with pymol [34].
Anti-microbial activity
The CM237 and akuB strains of Aspergillus fumigatus, that expresses CYP51, were used in this
work. Fungal strains were grown in Potato Dextrose Agar (PDA, Becton Dickinson, Madrid,
Spain) at 37°C. After three days of growth a suspension of spores was prepared by harvesting
the surface of the culture with phosphate buffered saline (PBS) plus 0.01% Tween 20. Inoculum
size was then adjusted using a hemocytometer chamber according to needs. Stock solutions of
each compound were first dissolved in chloroform and subjected to serial dilution to obtain the
concentrations of 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25 and 0.125 μg/ml. Each compound was tested
between 64 μg/ml and 0.125 μg/ml. Compounds susceptibility was determined by broth micro-
dilution (BMD) using RPMI 2% glucose. MICs were determined visually and recorded after 48
h. Amphotericin B and chloroform were used as controls of the study.
Conclusion
In this work, we synthesized novel AITs using 1-adamantyl bromomethylketone and 5-alkyl/
aryl-2-amino1,3,4-thiadiazoles employing nano-MgO in ionic liquid media. We experimen-
tally confirmed the anti-TB activity of all AITs againstM. tuberculosisH37Rv strain with MICs
in the low micromolar range. Subsequent docking studies revealed sterol 14α-demethylase
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(CYP51) as a plausible target, and subsequent activity determination against fungal strains that
express sterol 14α-demethylase (CYP51) corroborated this hypothesis. In summary, we herein
report the synthesis and anti-TB activity of novel AITs that likely target sterol 14α-demethylase
(CYP51) to induce their antimycobacterial activity.
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